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Abstract
Background: The combination of prophylactic pancreatic stent placement (PSP) – a temporary plastic stent placed
in the pancreatic duct – and rectal non-steroidal anti-inflammatory drugs (NSAIDs) is recommended for preventing
post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) in high-risk cases. Preliminary data,
however, suggest that PSP may be unnecessary if rectal NSAIDs are administered. Given the costs and potential
risks of PSP, we aim to determine whether rectal indomethacin obviates the need for pancreatic stent placement in
patients undergoing high-risk ERCP.
Methods/Design: The SVI (Stent vs. Indomethacin) trial is a comparative effectiveness, multicenter, randomized,
double-blind, non-inferiority study of rectal indomethacin alone versus the combination of rectal indomethacin and
PSP for preventing PEP in high-risk cases. One thousand four hundred and thirty subjects undergoing high-risk
ERCP, in whom PSP is planned solely for PEP prevention, will be randomized to indomethacin alone or
combination therapy. Those who are aware of study group assignment, including the endoscopist, will not be
involved in the post-procedure care of the patient for at least 48 hours. Subjects will be assessed for PEP and its
severity by a panel of independent and blinded adjudicators. Indomethacin alone will be declared non-inferior to
combination therapy if the two-sided 95 % upper confidence bound of the treatment difference is less than 5 %
between the two groups. Biological specimens will be obtained from trial participants and centrally banked.
Discussion: The SVI trial is designed to determine whether PSP remains necessary in the era of NSAIDs
pharmacoprevention. The associated bio-repository will establish the groundwork for important scientific
breakthrough.
Trial registration: NCT02476279, registered June 2015.
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Background
Based on clinical trial data, the combination of prophylac-
tic pancreatic stent placement (PSP) – a temporary plastic
stent placed in the pancreatic duct – and rectal non-
steroidal anti-inflammatory drug (NSAID) administration
is recommended for preventing post-endoscopic retro-
grade cholangiopancreatography (ERCP) pancreatitis
(PEP) in high-risk cases [1, 2]. PSP, however, is technically
challenging, time-consuming, costly, and potentially dan-
gerous [3–6]. Moreover, randomized controlled trials
(RCTs) demonstrating the efficacy of stent placement were
un-blinded in design and conducted by expert endosco-
pists who are highly skilled in pancreatic endotherapy, po-
tentially exaggerating the benefits of this intervention.
Secondary analysis of a large-scale multicenter RCT of
rectal indomethacin for preventing PEP in high-risk cases
suggested that subjects who received indomethacin alone
were less likely to develop PEP than those who received a
pancreatic stent alone or the combination of indometh-
acin and stent, even after adjusting for underlying differ-
ences in subject risk [7]. In addition, a recent network
meta-analysis comparing the data supporting PSP with
those supporting prophylactic NSAIDs demonstrated that
rectal NSAIDs alone are not inferior to combination ther-
apy [8]. This observation is biologically plausible because
a strategy of indomethacin alone avoids manipulation of
the pancreatic orifice and instrumentation of the pancre-
atic duct – interventions necessary to place a stent but
also known to contribute to the risk of PEP.
Given the costs and potential disadvantages of PSP,
minimizing its use in ERCP practice could result in
major clinical and economic benefits. Therefore, our aim
is to determine whether rectal indomethacin obviates
the need for PSP in patients undergoing high-risk ERCP.
Methods
Design
The Stent vs. Indomethacin (SVI) trial is a multicenter
randomized controlled trial designed to assess whether
rectal indomethacin alone is non-inferior by a pre-
specified amount to the combination of rectal indometh-
acin and PSP for preventing PEP in high-risk cases. The
study will take place at nine academic medical centers in
the United States. The Medical University of South
Carolina will serve as the statistical, data, and clinical co-
ordinating center as well as a clinical site. The remaining
eight medical centers will serve as clinical sites that en-
roll and follow study subjects. Ethical approval has been
obtained from the Institutional Review Boards of the
Medical University of South Carolina, Emory University,
Johns Hopkins University, University of Pittsburgh, Uni-
versity of Michigan, Case Western Reserve University,
University of Colorado, Washington University, and the
Florida Hospital.
Patients
The eligibility criteria are listed in Table 1. Informed
consent will be obtained from all study participants. We
plan to enroll adult patients at elevated risk for PEP who
require pancreatic stent placement for the sole purpose
of pancreatitis prevention. Patients will be considered to
be at high risk for PEP if their indication for PSP is one
of the following criteria: prior PEP, clinical suspicion of
sphincter of Oddi dysfunction, pancreatic sphincterot-
omy, precut sphincterotomy, difficult cannulation, or
short-duration pneumatic dilatation of an intact biliary
sphincter. Patients may also be included if they meet
two or more of the following criteria: age less than
50 years and female sex, a history of recurrent pancrea-
titis (at least two episodes), three or more injections of
contrast into the pancreatic duct, pancreatic acinariza-
tion, or pancreatic brush cytology. Patients will be ex-
cluded if they have standard contraindications to ERCP,
have a contraindication to the use of NSAIDs (e.g., al-
lergy, known renal failure, or active peptic ulcer disease),
have experienced recent acute pancreatitis, or have an
anticipated low risk of PEP (e.g., those with chronic cal-
cific pancreatitis, a pancreatic head mass, or those
undergoing biliary interventions through a pre-existing
sphincterotomy).
Procedure and interventions
All ERCP-related interventions with the exception of
stent placement will be dictated by the performing en-
doscopist. During the procedure, if an inclusion criterion
has been met and none of the exclusion criteria are
present and the papilla is accessible, the subject will be
randomized to receive 100 mg of rectal indomethacin
(two 50 mg suppositories) only or the combination of
prophylactic stent and 100 mg of rectal indomethacin.
Randomization will occur in a 1:1 fashion using a web-
based central randomization system that will ensure
treatment balance within site.
Indomethacin suppositories will be administered in all
subjects by an endoscopy nurse, technician, or the endos-
copist immediately after completion of the ERCP while
the patient is still in the endoscopy suite. The technique
by which prophylactic pancreatic stents are placed, and
the type of stent used, will not be directed by the study
protocol but rather deferred to the judgment of the endos-
copist. This approach is intended to mimic real-world
practice, wherein variations in stent type, caliber, and
length exist [9]. If a pancreatic stent is placed to facilitate
biliary access in a patient randomized to the indomethacin
alone arm, it will be removed before the end of the case.
Since intravenous fluid (IVF) type and rate may influence
the development of the primary and secondary endpoints
[10, 11], all decisions regarding IVF administration made
by the (unblinded) endoscopy team will be implemented
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prior to randomization. Subsequently, decisions pertaining
to IVF administration will be made by blinded clinical
personnel.
Since the endoscopist(s), endoscopy nurse, and techni-
cian/assistant involved in the ERCP will be aware of
whether or not a stent was placed, these individuals will
not be involved in the post-procedure care of the patient
for at least 48 hours after the procedure, at which point
the presence or absence of the primary endpoint (PEP)
will have become apparent. This approach is critical to
maintaining blinding (of patients, treating clinical
personnel, and outcome adjudicators), which ensures
equal co-interventions between study groups and un-
biased adjudication of the primary outcome. Addition-
ally, the endoscopy report and medical record will not
state whether a stent was placed. If the patient receives a
stent, they will be contacted 1–2 weeks after the ERCP
to arrange an abdominal radiograph to ensure spontan-
eous passage of the pancreatic stent.
Participating endoscopists will have the option of imple-
menting a provider-specific post-procedure order set that
is activated prior to randomization and executed uni-
formly regardless of a subject’s study group assignment.
This order set may include IVF, analgesic, and antiemetic
administration as well as parameters for hospital admis-
sion. If an order set is not available or has not been
activated, a designating blinded clinician will oversee the
post-procedure care of the patient. If a subject is
hospitalized, clinical decisions will be made by an in-
patient team which does not include the endoscopist
(or other unblinded personnel) for at least 48 hours
after the ERCP.
Follow-up
Subjects will be contacted 5 and 30 days after the ERCP.
The goal of the first follow-up is to ascertain data necessary
to adjudicate the primary endpoint. The goal of the second
follow-up is to ascertain data necessary to adjudicate the
Table 1 Eligibility criteria
Any patient undergoing endoscopic retrograde cholangiopancreatography (ERCP) in whom pancreatic stent placement is planned for post-ERCP
pancreatitis prevention, is at least 18 years old, provides informed consent, and:
Has one of the following criteria: Or two of the following criteria:
Clinical suspicion of sphincter of Oddi dysfunction Age under 50 years old and of female gender
History of post-ERCP pancreatitis History of recurrent pancreatitis
Pancreatic sphincterotomy At least 3 pancreatic injections, with at least 1 injection to tail
Pre-cut (access) sphincterotomy Pancreatic acinarization
Difficult cannulation Pancreatic brush cytology
Short duration (≤1 min) balloon dilation of intact biliary sphincter
Exclusion criteria
Ampullectomy
Case in which a pancreatic stent is placed for therapeutic intent
Unwillingness or inability to consent for the study
Pregnancy
Breastfeeding mother
Standard contraindications to ERCP
Allergy to aspirin or NSAIDs
Known renal failure (creatinine >1.4 mg/dl)
Ongoing or recent (within 2 weeks) hospitalization for gastrointestinal hemorrhage
Ongoing or recent (within 1 week) hospitalization for acute pancreatitis
Known chronic calcific pancreatitis
Pancreatic head mass
Procedure performed on major papilla/ventral pancreatic duct in patient with pancreas divisum (no manipulation of minor papilla)
ERCP for biliary stent removal or exchange without anticipated pancreatogram
Subjects with prior biliary sphincterotomy now scheduled for repeat biliary therapy without anticipated pancreatogram
Anticipated inability to follow protocol
Absence of rectum
NSAIDs non-steroidal anti-inflammatory drugs
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secondary outcome and assess for delayed serious adverse
events.
Outcomes
The primary outcome is PEP and the secondary outcome
is the severity of PEP. Using the consensus definition of
PEP as a diagnostic framework [12], three adjudicators
will independently assess study outcomes based on review
of a site-provided adverse event narrative and de-
identified medical records for each study subject hospital-
ized within 2 days after the ERCP. In order to ensure
blinding of the adjudicators, all information pertaining to
radiographic studies and prophylactic stent placement will
be redacted from the medical records.
Statistical considerations
Given the high economic and opportunity costs associ-
ated with pancreatic stent placement, as well as the risks
of attempted but unsuccessful insertion, we believe that
rectal indomethacin alone would become the dominant
strategy in clinical practice if we can demonstrate that it
results in less than a 5 % greater absolute PEP rate com-
pared to the combination of indomethacin and PSP. This
non-inferiority margin is based on a combination of stat-
istical reasoning and clinical judgment and was chosen
to ensure that the overall PEP proportion of the new
treatment (indomethacin alone) demonstrates a clinically
unimportant difference from the active comparator arm
(the combination of stent and indomethacin) as well as a
clinically relevant superiority over a putative placebo
(i.e., stent alone).
From a statistical perspective, the non-inferiority mar-
gin should retain at least 50 % of the superiority of the
combination of stent and indomethacin (the active con-
trol in the trial) when compared to stent alone [13, 14].
Our recent indomethacin RCT revealed that the abso-
lute risk difference in the proportion of subjects with
PEP between those who received indomethacin plus
stent versus those who received stent alone was 6.4 %
(95 % CI: 0.5 %, 12.3 %) [1]. Therefore, 50 % of this value
provides a non-inferiority margin of 3.2 %. Independent
to the statistical approach, a questionnaire was circu-
lated to ERCP experts regarding how much better (in
absolute terms) combination therapy would have to be
in preventing PEP as compared to indomethacin alone
to justify continuing its use in clinical practice. Seven of
11 respondents said that combination therapy would
have to be 10 % more effective and the remaining 4 said
that it had to be at least 5 % more effective. Based on
both the statistical and clinical information, the investi-
gators unanimously agreed upon a non-inferiority mar-
gin of 5 %, judging that a difference of greater than 5 %
constitutes an important difference in the risk of PEP.
The sample size was estimated using a confidence
interval approach focusing on the upper confidence limit
for a difference in proportions via simulations using
nQuery [15]. Based on the rate of PEP in the combin-
ation therapy group in our prior indomethacin RCT [1],
we estimated that 1300 subjects (650 per treatment
group) are necessary to achieve at least 85 % likelihood
of identifying less than a 5 % absolute difference in
PEP rates between the two treatment groups. The
intention-to-treat (ITT) principle will be applied to
the primary analysis and, therefore, to safeguard
against an approximate 5 % drop-in/out and missing
data rate in the two treatment groups, we increased
the sample size by a factor of 1.1 which is derived
from 1/(1−R)2, where R is the proportion of non-
adherence [16]. Thus a total of 1430 subjects will be
enrolled and randomized.
For the analysis of the primary outcome, the two-
sided 95 % upper confidence bound (equivalent to the
one-sided 97.5 % upper confidence bound) of the ob-
served risk difference in the proportion of patients
developing PEP between the two treatment groups
will be calculated. Indomethacin alone will be de-
clared non-inferior to combination therapy if the two-
sided 95 % upper confidence bound of the treatment
difference is less than 5 %. If indomethacin is found
to be non-inferior, an analysis for superiority will be
conducted using a one-sided two-sample test for in-
dependent binomial proportions.
Two interim analyses for futility using conditional
power will be conducted when approximately one
third (N is approximately 472) and two thirds (N is
approximately 958) of the total required number of
randomized subjects have been evaluated for the pri-
mary outcome and all of the outcomes to be used in
the analysis are adjudicated. The goal of the interim
analysis plan is to determine whether to stop the trial
early because it is unlikely to show non-inferiority at
the final analysis. A conditional power will be calcu-
lated to assess the probability of observing non-
inferiority at the final analysis conditional on the
observed data and assumptions on the PEP event
rates for the remainder of the trial [17].
Clinical monitoring
A comprehensive site monitoring plan aims to ensure
that the trial is conducted in accordance with the ap-
proved protocol, regulatory standards, and good clin-
ical practice. Verification of study and regulatory
documents will be conducted remotely. Scheduled
and “for-cause” on site monitoring visits to each cen-
ter will be conducted to verify study data and out-
comes relative to source documents and to ensure
compliance with study procedures.
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Discussion
Prophylactic pancreatic stent placement is thought to re-
duce the risk of PEP by relieving pancreatic ductal
hypertension that develops due to procedure-induced
edema and stenosis of the pancreatic orifice [4, 18, 19].
PSP, however, is not completely effective because other
pathophysiologic mechanisms, such as chemical, allergic,
enzymatic, and infectious injury also contribute to PEP
[19] and may be induced or potentiated by the process
of placing a pancreatic stent. Indeed, the superiority of
indomethacin mono-prevention over any strategy involv-
ing PSP is mechanistically plausible because the indo-
methacin strategy avoids manipulation of the pancreatic
orifice and instrumentation of the pancreatic duct.
Indomethacin mono-prevention may offer several add-
itional advantages over combination therapy. First, such a
strategy avoids the phenomenon of attempted but failed
PSP, which is associated with a high rate of PEP by activat-
ing aforementioned pathogenic factors but providing no
ductal decompression [6]. It would also eliminate the 4 %
of cases that result in significant non-pancreatitis adverse
events induced by PSP, such as stent migration and duct
perforation [20], as well as the rare adverse events that
occur during follow-up upper endoscopy to remove
retained stents. It would substantially reduce healthcare
expenditures by eliminating the cost of stent placement in
most cases, as well as eliminating the need for follow-up
abdominal radiography (to ensure spontaneous passage of
the stent) and follow-up upper endoscopies to remove
retained stents. Indeed, a cost-benefit analysis revealed
that a prevention strategy employing rectal indomethacin
alone could save approximately US$150 million annually
in the United States compared with a strategy of PSP
alone, and US$85 million compared with a strategy of
indomethacin and PSP [7]. Finally, it would allow broader
delivery of endoscopic care (particularly in resource-
limited environments) by allowing additional time for
other endoscopic procedures and interventions.
The SVI trial is a reappraisal of the effectiveness of
PSP in the era of NSAID pharmacoprevention and an
opportunity to address the main limitations of prior
stent studies – the lack of blinding and the unclear
generalizability of the results. The SVI trial will be the
first PSP RCT to blind subjects, caregivers, and out-
comes assessors. Given the potential impact of co-
interventions (IVF, analgesics) on the outcome and the
subjective nature of the definition of PEP, blinding in
such a trial is necessary to minimize bias in the care of
patients and in the adjudication of outcomes. Indeed,
the benefit of PSP may have been exaggerated in prior
studies because of differential care of patients who have
received stents patients (closer observation, more
aggressive IVF administration, etc.) or biased interpret-
ation of the definition of PEP based on study group
assignment. Furthermore, the large number of partici-
pating centers and endoscopists in the SVI trial will
allow a broader assessment of the impact of practice and
skill variations on the effectiveness of PSP, augmenting
the generalizability of the results.
A PSP alone arm is not included in this study because
such a strategy is unlikely to remain clinically viable. Ro-
bust clinical trial data confirm the essential role of rectal
indomethacin in clinical practice and the European Society
of Gastrointestinal Endoscopy guidelines recommend rec-
tal indomethacin or diclofenac to all patients undergoing
ERCP as a grade A recommendation [2, 21, 22]. In light of
this evidence-base, and considering that indomethacin is
very safe and inexpensive, PSP alone no longer plays a role
in high-risk patients without contraindications to a single
dose of NSAIDs. The time and cost necessary to include a
stent alone arm in this RCT were not considered justifi-
able, and the investigators felt that withholding indometh-
acin from high-risk study subjects would represent
suboptimal care.
A major focus of the SVI trial is to establish a reposi-
tory of biological specimens from study subjects upon
which future translational studies can be conducted. To
further explore the pathophysiology of acute pancrea-
titis, the molecular predictors of severity, the mecha-
nisms by which indomethacin protects against PEP, and
other important questions, we will obtain and bank
whole blood, serum, plasma, urine, stool, and duodenal
fluid from trial participants. The SVI investigators and
translational research committee are developing a con-
ceptual framework of translational research initiatives
using bio-repository samples, including comparisons of
indomethacin levels, conventional measures of inflam-
mation and drug activity, as well as comparisons of gen-
etic, microbial, and host/bacterial metabolomic profiles
between subjects who do and do not develop PEP.
Summary
The SVI trial is a natural next step in the advancement
of our understanding of PEP prevention by answering a
critically important clinical question: can we replace an
invasive and costly preventive strategy with a safe and
inexpensive one? Through the conduct of this study we
hope to determine whether PSP remains necessary in
the era of NSAIDs pharmacoprevention. In the process,
we will establish the groundwork for major translational
research breakthroughs in the fields of endoscopy and
pancreatology.
Trial status
This randomized controlled trial began enrolling patients
in September of 2015.
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